Diagnosis of PV necessitates the presence of a JAK2 mutation, plus increased hemoglobin/hematocrit (>16.5 g/dL or 49% for males and >16 g/dL or 48% for females), based on the 2016 World Health Organization (WHO) revised criteria.[1,2]The clinical manifestations of PV are variables, including fatigue, pruritis, features of hyperviscosity, thrombotic events, bleeding complications, and splenomegaly. Here, JAK2 is linked to acquired polycythemia vera.